Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olanzapine vs Aripiprazole in Schizophrenia
NCT00088049Phase 4Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of olanzapine in schizophrenia (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Time to all-cause treatment discontinuation at 28 weeks. Started Oct 2003; status: completed.
02
Drugs
olanzapine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00088049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00088049.